Vanguard Group Inc Nutri Band Inc. Transaction History

Vanguard Group Inc

$5.97 Trillion
Q2 2025

A detailed history of Vanguard Group Inc transactions in Nutri Band Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 199,627 shares of NTRB stock, worth $1.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

199,627

Previous 199,027 0.3%

Holding current value

$1.41 Million

Previous $1.22 Million 28.77%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	BUY	$4.72 - $8.18 $2,832 - $4,908	600 Added 0.3%	199,627 $1.57 Million
Q1 2025 May 09, 2025	BUY	$4.07 - $9.39 $302,958 - $698,963	74,437 Added 59.75%	199,027 $1.22 Million
Q4 2024 Feb 11, 2025	BUY	$3.85 - $8.39 $25,128 - $54,761	6,527 Added 5.53%	124,590 $574,000
Q3 2024 Nov 13, 2024	BUY	$3.84 - $9.25 $33,381 - $80,410	8,693 Added 7.95%	118,063 $714,000
Q2 2024 Aug 13, 2024	BUY	$3.35 - $6.16 $75,609 - $139,031	22,570 Added 26.0%	109,370 $590,000
Q1 2024 May 10, 2024	BUY	$2.3 - $4.52 $3,624 - $7,123	1,576 Added 1.85%	86,800 $392,000
Q3 2023 Nov 14, 2023	BUY	$2.38 - $4.63 $19,106 - $37,169	8,028 Added 10.4%	85,224 $217,000
Q2 2023 Aug 14, 2023	BUY	$2.04 - $3.86 $39,739 - $75,192	19,480 Added 33.75%	77,196 $231,000
Q4 2022 Feb 10, 2023	BUY	$3.53 - $4.5 $12,482 - $15,912	3,536 Added 6.53%	57,716 $207,000
Q3 2022 Nov 14, 2022	BUY	$3.49 - $7.83 $80,461 - $180,520	23,055 Added 74.07%	54,180 $195,000
Q2 2022 Aug 12, 2022	SELL	$2.81 - $5.69 $13,184 - $26,697	-4,692 Reduced 13.1%	31,125 $128,000
Q1 2022 May 13, 2022	BUY	$3.3 - $9.43 $118,196 - $337,754	35,817 New	35,817 $151,000

Others Institutions Holding NTRB

# of Institutions

Shares Held

346K

Call Options Held

Put Options Held

View Full List

About NutriBand Inc.

Ticker NTRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,803,260
Market Cap $55.2M
Description
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid the...

More about NTRB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Nutri Band Inc. Transaction History